Follicular lymphoma: life beyond the third line

Affiliations

Comment

Silvia Montoto. Lancet Haematol. 2022 Apr.

. 2022 Apr;9(4):e241-e242.

doi: 10.1016/S2352-3026(22)00043-6.

¹ Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK. Electronic address: s.montoto@qmul.ac.uk.

No abstract available

Conflict of interest statement

I declare a speaking fee from Janssen and participation on a data monitoring committee for Bayer.

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Casulo C, et al. Lancet Haematol. 2022 Apr;9(4):e289-e300. doi: 10.1016/S2352-3026(22)00033-3. Lancet Haematol. 2022. PMID: 35358443 Free PMC article.